Cannabidiol for lennox gastaut syndrome

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 10 registered trials.

Why this status

  1. 25 Aug 2014: Trial registered, NCT02224560
  2. 25 Aug 2014: Trial registered, NCT02224573
  3. 25 Aug 2014: Trial registered, NCT02224690
  4. 17 Dec 2014: Trial registered, NCT02318602
  5. 28 Apr 2015: Trial started, NCT02224690
  6. 8 Jun 2015: Trial started, NCT02224560
  7. 11 Jun 2015: Trial started, NCT02224573
  8. 8 Jan 2016: Trial started, NCT02318602
  9. 7 Jul 2021: Trial started, NCT05044819
  10. 16 Sep 2021: Trial registered, NCT05044819

The trials

NCT02224560: Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

State
Completed
Phase
Phase 3
People
225 taking part
Started
8 Jun 2015
Primary completion
19 May 2016
Arms
GWP42003-P 20 mg/kg/day Dose, GWP42003-P 10 mg/kg/day Dose
Results
Posted on the registry
Papers
doi:10.1002/14651858.cd003277.pub4, doi:10.1007/s40263-025-01201-8, doi:10.1056/nejmoa1714631, doi:10.1111/epi.16878, doi:10.1111/epi.17618, doi:10.1177/1535759719835671
  1. 25 Aug 2014: Trial registered
  2. 8 Jun 2015: Trial started
  3. 19 May 2016: Trial completed
  4. 27 Jul 2018: Trial results posted

NCT02224573: An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes

State
Completed
Phase
Phase 3
People
681 taking part
Started
11 Jun 2015
Primary completion
24 Sep 2020
Arms
GWP42003-P
Results
Posted on the registry
Papers
doi:10.1111/epi.17000, doi:10.1111/epi.17036
  1. 25 Aug 2014: Trial registered
  2. 11 Jun 2015: Trial started
  3. 24 Sep 2020: Trial completed
  4. 3 Feb 2022: Trial results posted

NCT02224690: A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

State
Completed
Phase
Phase 3
People
171 taking part
Started
28 Apr 2015
Primary completion
18 Mar 2016
Arms
GWP42003-P 20 mg/kg/day Dose
Results
Posted on the registry
Papers
doi:10.1002/14651858.cd003277.pub4, doi:10.1007/s40263-025-01201-8, doi:10.1016/s0140-6736(18)30136-3, doi:10.1111/epi.16878, doi:10.1111/epi.17618
  1. 25 Aug 2014: Trial registered
  2. 28 Apr 2015: Trial started
  3. 18 Mar 2016: Trial completed
  4. 27 Jul 2018: Trial results posted

NCT02318537: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome

State
Withdrawn before it started
Phase
Phase 3
People
0 taking part
Started
30 Dec 2017
Primary completion
30 Jun 2018
Arms
Cannabidiol Oral Solution
Results
None posted
  1. 17 Dec 2014: Trial registered
  2. 4 Jan 2018: Trial withdrawn

NCT02318602: Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

State
Completed
Phase
Phase 3
People
52 taking part
Started
8 Jan 2016
Primary completion
22 Jun 2017
Arms
Infants, Children, Adolescents
Results
Posted on the registry
  1. 17 Dec 2014: Trial registered
  2. 8 Jan 2016: Trial started
  3. 22 Jun 2017: Trial completed
  4. 26 Jul 2018: Trial results posted

NCT04133480: Investigation of Cognitive Outcomes With Cannabidiol Oral Solution

State
Withdrawn before it started
Phase
Phase 4
People
0 taking part
Started
Oct 2020
Primary completion
Dec 2021
Arms
GWP42003-P
Results
None posted
  1. 21 Oct 2019: Trial registered
  2. 1 Sep 2022: Trial withdrawn

NCT04485104: Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

State
Stopped early
Phase
Phase 3
People
3 taking part
Started
19 May 2021
Primary completion
28 Jan 2025
Arms
GWP42003-P
Results
Posted on the registry
  1. 24 Jul 2020: Trial registered
  2. 19 May 2021: Trial started
  3. 28 Jan 2025: Trial terminated
  4. 31 Oct 2025: Trial results posted

NCT05044819: Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

State
Under way
Phase
Phase 4
People
154 taking part
Started
7 Jul 2021
Primary completion
1 Aug 2027
Arms
Cannabidiol
Results
None posted
  1. 7 Jul 2021: Trial started
  2. 16 Sep 2021: Trial registered

NCT06924827: A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex

State
Not started
Phase
Phase 4
People
25 planned
Started
1 Jan 2027
Primary completion
1 Jan 2028
Arms
Epidiolex Treatment
Results
None posted
  1. 11 Apr 2025: Trial registered

NCT07728097: A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS

State
Not started
Phase
Phase 4
People
40 planned
Started
18 Nov 2026
Primary completion
28 Dec 2028
Arms
Cannabidiol Oral Solution Treatment group
Results
None posted
  1. 27 Jul 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Cardiolrx, Canapure PH, Cannabidiol (Epidiolex), Cannabidiol Oral Solution, Epidiolex, Epidiolex 100 mg/mL Oral Solution, Epidyolex, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose, GWP42003-P 5 mg/kg/day Dose, MediCabilis.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.